--- title: "What 5 Years of Autism Research Actually Found (2020–2025): A Fully Sourced Review" slug: autism-research-2020-2025 category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-05-27 tags: ["autism", "ASD", "research", "CDC", "NIMH", "NIH", "FDA", "neurodiversity"] read_time_minutes: 18 canonical_url: https://brainwavepost.com/article/autism-research-2020-2025 source: BrainWavePost --- # What 5 Years of Autism Research Actually Found (2020–2025): A Fully Sourced Review *Health · 2026-05-27 · BrainWavePost Staff · 18 min read* > A careful, inline-cited summary of major autism (ASD) research published between 2020 and 2025 — drawn only from the CDC, NIH, NIMH, NIEHS, FDA and top peer-reviewed journals. Not medical advice; the author is not a medical professional. > **Please read this first** _(note)_ > > The author of this article is NOT a medical professional. Nothing here is medical advice, a diagnosis, a recommended treatment, or a suggestion to start, stop or change any therapy, medication or intervention. The studies summarised below are research findings — they are not approved treatments, cures or clinical guidelines. For anything concerning yourself or a family member, please consult a qualified healthcare professional. > **How this article is sourced** _(info)_ > > Every numeric figure, study claim and quoted definition below links to a primary source: the U.S. Centers for Disease Control and Prevention (CDC), the National Institute of Mental Health (NIMH), the National Institutes of Health (NIH), the National Institute of Environmental Health Sciences (NIEHS), the U.S. Food and Drug Administration (FDA), or peer-reviewed journals (Cell, Nature Genetics, NEJM, Communications Biology, Translational Psychiatry, Environmental Health Perspectives, JAACAP). Each numbered citation [n] links to a URL in the References section at the end. No statistic or claim has been added that is not in those sources. Autism spectrum disorder (ASD) is a developmental condition that affects how a person communicates, learns and experiences the world. Research between 2020 and 2025 has produced clearer prevalence data, important genetic findings and several intervention trials — including trials that failed. This review walks through what reputable agencies have actually reported in those five years, with an inline citation on each line. [1][2][3] Because this is a research review, two things are deliberately avoided throughout: (a) any recommendation, suggestion or guidance about what to do, and (b) any number or claim that is not directly traceable to one of the cited primary sources. [1][2][3] ## 1. How common is autism? CDC ADDM prevalence (2020–2025) The CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network reports ASD prevalence among 8-year-old children at multiple U.S. sites. Its surveillance estimates published during 2020–2025 are as follows. [1][2][3] ### 2018 surveillance year — 1 in 44 children Using 2018 data across 11 ADDM sites, the CDC reported that 1 in 44 (2.3%) 8-year-old children had been identified with ASD, up from 1 in 54 in the prior cycle. [1] ### 2020 surveillance year — 1 in 36 children Using 2020 data across 11 ADDM sites, the CDC reported that about 1 in 36 (2.76%) 8-year-old children had been identified with ASD. Prevalence among boys was 1 in 23 and among girls 1 in 76, a male-to-female ratio of approximately 3.8:1. [2] ### 2022 surveillance year — 1 in 31 children Using 2022 data across 16 ADDM sites, the CDC reported ASD prevalence of approximately 1 in 31 (3.2%) among 8-year-old children — the highest estimate recorded by the network to date. The 4-year-old cohort in the same report was identified at 1 in 36. [3] > **Why the numbers keep going up** _(note)_ > > The CDC explicitly states that ADDM prevalence is an identification rate, not a measure of how common ASD truly is in the population. Increases over time reflect a combination of broader diagnostic criteria, more screening and better access to evaluation, alongside any real change in prevalence. [1][2][3] - **1 in 44** — 8-year-olds identified with ASD (2018 data, published 2021) [1] - **1 in 36** — 8-year-olds identified with ASD (2020 data, published 2023) [2] - **1 in 31** — 8-year-olds identified with ASD (2022 data, published 2025) [3] ## 2. Genetics: what large 2020–2022 studies found A 2020 study in Cell by the Autism Sequencing Consortium analysed exome sequencing data from 35,584 samples (including roughly 11,986 ASD cases) and identified 102 genes associated with ASD risk; the authors reported these genes are predominantly expressed in excitatory neurons and linked to fetal brain development and synaptic function. [4] A 2021 Nature Genetics paper using whole-genome sequencing from 3,474 SPARK families reported that ultra-rare inherited variants contribute to ASD risk on a scale comparable to de novo mutations — a shift from the earlier emphasis on new mutations alone. [5] A 2022 Nature Genetics paper using SPARK data from approximately 43,000 participants with autism described a group of inherited genes of moderate effect and reported overlap with other behavioural conditions. [6] > **What this does NOT mean** _(info)_ > > Identifying risk genes is not the same as identifying a cause, a test or a treatment. The cited papers describe statistical associations between genetic variants and ASD risk in research cohorts; they do not establish that any single gene causes autism in any individual person. [4][5][6] ## 3. Early identification and screening An NIMH-supported study reported that adding a two-stage screening approach (M-CHAT-R/F plus direct observation) inside Part C Early Intervention programmes improved detection rates and reduced racial/ethnic disparities in early ASD identification, according to NIMH's 2022 summary. [7] An NIMH science update in 2023 described research finding that machine-learning models applied to routine infant electronic health record data could flag children at elevated ASD likelihood as early as 12–18 months — earlier than standard M-CHAT screening at 18–24 months. [8] The CDC's 2023 ADDM Community Report noted that early identification of ASD at age 4 was disrupted during the COVID-19 pandemic, with fewer timely evaluations recorded in 2020. [9] ## 4. Sex and gender differences in identification In the CDC's 2020 ADDM data (published 2023), boys were 3.8 times more likely than girls to be identified with ASD (1 in 23 boys vs 1 in 76 girls among 8-year-olds). [2] The same CDC surveillance report notes that girls historically receive their first comprehensive ASD evaluation and diagnosis at older ages than boys, contributing to delayed access to early services. [2] ## 5. Co-occurring conditions A CDC MMWR Weekly study (Powell et al., 2021) using 2018–2020 data from four U.S. sites reported that adolescents identified with ASD in early childhood had significantly higher rates of co-occurring health conditions — including ADHD, anxiety, depression and gastrointestinal conditions — and greater healthcare utilisation than peers without ASD. [10] A 2023 CDC-affiliated analysis reported that approximately 33% of ADDM-identified children with ASD also had a co-occurring intellectual disability, with higher rates of documented epilepsy, GI problems and psychiatric conditions in that subgroup than in children with ASD alone. [11] ## 6. Brain imaging studies A 2020 study in Translational Psychiatry (Nature Portfolio) using neonatal functional MRI reported measurable differences in functional brain connectivity at birth in newborns with a sibling with ASD, particularly in networks related to social processing. [12] A 2024 Communications Biology (Nature Portfolio) study reported altered salience-network functional connectivity in 6-week-old infants at heightened likelihood of developing ASD. [13] An NIMH science news article in 2023 described research in which some toddlers later identified with ASD showed a distinctive preference for looking at geometric images over social images, detected via brief eye-tracking. [14] > **Imaging findings are not diagnostic tools** _(note)_ > > None of the brain imaging or eye-tracking findings above is, by itself, a clinical test for autism. They are research observations published in peer-reviewed journals; clinical ASD diagnosis continues to be based on comprehensive developmental evaluation. [12][13][14] ## 7. Intervention research (including a notable failed trial) A multisite NIH-funded randomized controlled trial published in 2020 (Kasari et al., Journal of the American Academy of Child & Adolescent Psychiatry, N = 87 children aged 27–54 months) reported that the style of early intervention (naturalistic/developmental vs structured/behavioural) had a greater effect on outcomes than the number of therapy hours. [15] A 24-week, placebo-controlled Phase 2 randomized controlled trial of intranasal oxytocin in children and adolescents aged 3–17 with ASD, published in the New England Journal of Medicine in 2021 (Sikich et al.), reported NO statistically significant improvement over placebo on the primary outcome (Aberrant Behavior Checklist–modified Social Withdrawal subscale) and no benefit across other social-function measures. [16] A 2023 NIH-funded multisite RCT of early intervention approaches for minimally verbal preschoolers with ASD and global developmental delay reported that naturalistic developmental behavioral interventions (NDBIs) produced statistically significant improvements in spoken language outcomes compared with the comparison condition. [17] > **Research ≠ approved treatment** _(note)_ > > The studies above describe research outcomes in defined populations under trial conditions. They are not endorsements of any specific therapy programme, provider or product, and they do not constitute clinical guidance. [15][16][17] ## 8. Adult outcomes A CDC analysis published in 2020 (Dietz et al., NCBDDD) estimated approximately 2.21 million adults in the United States have ASD, with state-level estimates ranging from 1.97% to 2.42% of adults. [18] A CDC page on ASD in teenagers and adults (updated April 15, 2025), citing longitudinal follow-up work, notes that fewer than 20% of young adults with ASD were reported as working in the community or living independently without family or residential support in the years following high school transition. [19] ## 9. Health disparities in diagnosis by race and ethnicity Per the CDC's 2020 ADDM data published in 2023, ASD prevalence among Black children (2.9%) and Hispanic children (2.8%) was equal to or higher than among White children (2.4%) at several ADDM sites — a reversal of the longstanding underidentification gap. [2][20] The CDC notes this convergence likely reflects improved access to evaluation in those communities rather than fully equitable outcomes, and that socioeconomic, geographic and service-access disparities persist. [20] ## 10. FDA-approved medications: what does and does not exist As of 2025, the FDA has NOT approved any drug to treat the core symptoms of ASD (social communication differences and restricted/repetitive behaviours). The only FDA-approved medications labelled for ASD-associated symptoms are risperidone and aripiprazole, both approved for irritability associated with autism (risperidone since 2006; aripiprazole since 2009), not for core ASD symptoms. [21][22] On March 10, 2023, the FDA approved Daybue (trofinetide) oral solution as the first treatment for Rett syndrome in adults and children aged 2 years and older. Rett syndrome is a distinct genetic condition caused by MECP2 mutations and, although historically grouped with ASD, is not the same as autism; Daybue is not approved for ASD broadly. [23] The 2021 NEJM oxytocin trial discussed in Section 7 is a notable example of a high-profile candidate treatment for ASD social symptoms that did NOT meet its primary endpoint. [16] ## 11. Environmental and prenatal risk-factor research A 2022 study in Environmental Health Perspectives (a NIEHS journal) reported that prenatal exposure to fine particulate matter (PM2.5) was associated with increased ASD risk in the studied cohort, with sensitive windows identified particularly in the third trimester and stronger associations in male children. [24] > **Important methodological caveat** _(note)_ > > Environmental risk-factor studies for ASD are largely epidemiological — they describe statistical associations, not proven causes. The CDC and NIH consistently state that no single environmental factor has been established as a direct cause of ASD, and that ASD is understood to arise from a complex interaction of genetic susceptibility and environmental influences. [24] ## 12. What this article does not cover - Any claim that autism is caused by vaccines — extensive prior research has not supported that claim, and no 2020–2025 study cited here makes such a claim. - Any specific therapy programme, app, supplement, diet or device — none is endorsed or recommended here. - Country-by-country comparisons of prevalence — the figures above come from U.S. CDC surveillance and are not directly comparable to figures from other countries' systems. - Clinical guidance — for personal decisions, please consult a qualified healthcare professional. ## 13. Key takeaways - CDC ADDM identification of ASD among 8-year-olds in the U.S. rose from 1 in 44 (2018 data) to 1 in 36 (2020 data) to 1 in 31 (2022 data) across the 2020–2025 publication window. [1][2][3] - Large 2020–2022 genetic studies identified more than 100 ASD-associated genes and showed that ultra-rare inherited variants contribute substantially to risk, alongside de novo mutations. [4][5][6] - Brain imaging and eye-tracking research has detected group-level differences in infants and toddlers later identified with ASD, but these are research findings, not diagnostic tests. [12][13][14] - Intervention research has shown that style of early intervention can matter more than sheer hours, while a major 2021 NEJM trial of intranasal oxytocin failed to show benefit on its primary endpoint. [15][16] - No FDA-approved drug targets the core symptoms of ASD; risperidone and aripiprazole are approved only for irritability associated with autism, and Daybue (2023) is approved specifically for Rett syndrome, not ASD broadly. [21][22][23] > **Editorial note** _(info)_ > > BrainWavePost.com is independent. This article only summarises published research from the cited primary sources between 2020 and 2025. No figures have been invented, and no recommendations are made. The author is not a medical professional. ## References (clickable) - [1] CDC press release on 2018 ADDM data (1 in 44): https://archive.cdc.gov/www_cdc_gov/media/releases/2021/p1202-autism.html - [2] CDC MMWR Surveillance Summaries, Vol. 72, No. 2 — 2020 ADDM data (1 in 36): https://www.cdc.gov/mmwr/volumes/72/ss/ss7202a1.htm - [3] CDC MMWR Surveillance Summaries, Vol. 74, No. 2 — 2022 ADDM data (1 in 31): https://www.cdc.gov/mmwr/volumes/74/ss/pdfs/ss7402a1-H.pdf - [4] Satterstrom et al., Cell, Feb 6 2020 — 102 ASD risk genes: https://www.sciencedirect.com/science/article/pii/S0092867419313984 - [5] SPARK / Eichler lab, Nature Genetics, Sept 2021 — inherited variants in ASD: https://www.nature.com/articles/s41588-021-00899-8 - [6] SPARK Consortium, Nature Genetics, Aug 2022 — moderate-effect inherited genes: https://www.nature.com/articles/s41588-022-01104-0 - [7] NIMH science news, 2022 — multi-stage screening in Early Intervention: https://www.nimh.nih.gov/news/science-news/2022/multistage-autism-screening-in-early-intervention-settings-may-reduce-disparities - [8] NIMH science update, 2023 — infant EHR data and early ASD screening: https://www.nimh.nih.gov/news/science-updates/2023/infants-health-record-data-may-improve-early-autism-screening - [9] CDC ADDM Community Report, 2023 — COVID-19 impact on early identification: https://archive.cdc.gov/www_cdc_gov/ncbddd/autism/addm-community-report/key-findings.html - [10] Powell et al., CDC MMWR Weekly, Vol. 70 No. 17, April 30 2021 — co-occurring conditions in adolescents with ASD: https://www.cdc.gov/mmwr/volumes/70/wr/mm7017a1.htm - [11] CDC / Johns Hopkins analysis on ID and ASD co-occurrence (2023): https://stacks.cdc.gov/view/cdc/123518 - [12] Ciarrusta et al., Translational Psychiatry, 2020 — neonatal connectivity in ASD risk: https://www.nature.com/articles/s41398-020-0805-y - [13] Tsang et al., Communications Biology, 2024 — salience network in 6-week-old infants: https://www.nature.com/articles/s42003-024-06016-9 - [14] NIMH science news, 2023 — geometric image preference as toddler biomarker: https://www.nimh.nih.gov/news/science-news/2023/attention-to-geometric-images-may-offer-biomarker-for-some-toddlers-with-autism - [15] Kasari et al., JAACAP, 2020 — intervention style vs intensity RCT (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC8057785/ - [16] Sikich et al., New England Journal of Medicine, Sept 2021 — intranasal oxytocin RCT (no benefit): https://www.nejm.org/doi/full/10.1056/NEJMoa2103583 - [17] Kasari et al., 2023 NIH-funded RCT on early intervention for minimally verbal preschoolers (PubMed): https://pubmed.ncbi.nlm.nih.gov/37070270/ - [18] Dietz et al., CDC/NCBDDD, 2020 — ~2.21M U.S. adults with ASD: https://stacks.cdc.gov/view/cdc/119183 - [19] CDC — Autism Spectrum Disorder in Teenagers and Adults (updated 2025): https://www.cdc.gov/autism/about/asd-in-teenagers-adults.html - [20] CDC ADDM 2023 community report — closing racial identification gaps: https://archive.cdc.gov/www_cdc_gov/ncbddd/autism/addm-community-report/spotlight-on-closing-racial-gaps.html - [21] FDA — Risperidone approval record: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021444 - [22] FDA — Aripiprazole pediatric labelling document including irritability associated with autism indication: https://www.fda.gov/media/89198/download - [23] FDA — Approval of Daybue (trofinetide) for Rett syndrome, March 10 2023: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome - [24] Environmental Health Perspectives (NIEHS), Vol. 130 Issue 1, 2022 — prenatal PM2.5 and ASD risk: https://ehp.niehs.nih.gov/doi/10.1289/EHP9509 --- _Canonical article: [https://brainwavepost.com/article/autism-research-2020-2025](https://brainwavepost.com/article/autism-research-2020-2025) — © BrainWavePost. Educational content; see the article page for full disclaimers._